报价延迟最少15分钟:2026/02/24 22:22 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.7 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.79/-0.74
|
|
企业价值
106.57M
|
| 资产负债 |
|
每股账面净值
0.72
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
683.00K
|
|
每股收益
0.01
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States. |
